JP Morgan Private Wealth Advisors’s Juno Therapeutics, Inc. JUNO Stock Holding History

JP Morgan Private Wealth Advisors’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-5,935	Closed	-$229K	–	1301
2016 Q2	$229K	Buy	+5,935	New	+$246K	﹤0.01%	1104
2016 Q1	–	Sell	-4,900	Closed	-$215K	–	1331
2015 Q4	$215K	Buy	+4,900	New	+$243K	﹤0.01%	996
2015 Q3	–	Sell	-8,750	Closed	-$466K	–	1187
2015 Q2	$466K	Sell	8,750 -1,500	-15%	-$79.6K	0.01%	702
2015 Q1	$621K	Buy	+10,250	New	+$497K	0.01%	645

Other funds holding JUNO

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCM

Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

JP Morgan Private Wealth Advisors's JUNO Position: Q3 2016 in Review

JP Morgan Private Wealth Advisors sold out of Juno Therapeutics, Inc. (JUNO) in Q3 2016, closing a stake of 5,935 shares — an estimated $229K sold.

JP Morgan Private Wealth Advisors first reported a position in JUNO in Q1 2015 and held it in 4 quarters. The position peaked at $621K in Q1 2015. 169 funds tracked by Wall St. Rank hold JUNO as of Q3 2016.

JP Morgan Private Wealth Advisors reported no remaining Juno Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
JP Morgan Private Wealth Advisors sold 5,935 Juno Therapeutics, Inc. shares in Q3 2016, an estimated $229K.
JP Morgan Private Wealth Advisors first reported a position in Juno Therapeutics, Inc. in Q1 2015 and held it in 4 quarters.
JP Morgan Private Wealth Advisors's Juno Therapeutics, Inc. position peaked at $621K in Q1 2015.
169 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q3 2016.

Based on JP Morgan Private Wealth Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.